Pilot study of natural human interleukin-2 in patients with chronic hepatitis B. Immunomodulatory and antiviral effects (Q72756384)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8301059%20AND%20SRC:MED&resulttype=core&format=json

29 October 2019

title

Pilot study of natural human interleukin-2 in patients with chronic hepatitis B. Immunomodulatory and antiviral effects (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8301059%20AND%20SRC:MED&resulttype=core&format=json

29 October 2019

1 reference

H Tilg

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8301059%20AND%20SRC:MED&resulttype=core&format=json

29 October 2019

W Vogel

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8301059%20AND%20SRC:MED&resulttype=core&format=json

29 October 2019

J Tratkiewicz

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8301059%20AND%20SRC:MED&resulttype=core&format=json

29 October 2019

W E Aulitzky

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8301059%20AND%20SRC:MED&resulttype=core&format=json

29 October 2019

M Herold

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8301059%20AND%20SRC:MED&resulttype=core&format=json

29 October 2019

M Gruber

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8301059%20AND%20SRC:MED&resulttype=core&format=json

29 October 2019

D Geissler

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8301059%20AND%20SRC:MED&resulttype=core&format=json

29 October 2019

F Umlauft

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8301059%20AND%20SRC:MED&resulttype=core&format=json

29 October 2019

G Judmaier

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8301059%20AND%20SRC:MED&resulttype=core&format=json

29 October 2019

U Schwulera

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8301059%20AND%20SRC:MED&resulttype=core&format=json

29 October 2019

publication date

1 September 1993

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8301059%20AND%20SRC:MED&resulttype=core&format=json

29 October 2019

published in

Journal of Hepatology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8301059%20AND%20SRC:MED&resulttype=core&format=json

29 October 2019

volume

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8301059%20AND%20SRC:MED&resulttype=core&format=json

29 October 2019

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8301059%20AND%20SRC:MED&resulttype=core&format=json

29 October 2019

page(s)

259-267

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8301059%20AND%20SRC:MED&resulttype=core&format=json

Randomized, controlled trial of recombinant human alpha-interferon in patients with chronic hepatitis B

29 October 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980580-X

7 January 2021

A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980580-X

7 January 2021

Interleukin-2 enhances the depressed natural killer and cytomegalovirus-specific cytotoxic activities of lymphocytes from patients with the acquired immune deficiency syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980580-X

7 January 2021

The reconstitution of cell-mediated immunity in the cutaneous lesions of lepromatous leprosy by recombinant interleukin 2.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980580-X

7 January 2021

Interleukin-1 and interleukin-2 activity in chronic hepatitis B virus infection.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980580-X

7 January 2021

Pilot study of recombinant human interleukin 2 for chronic type B hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980580-X

7 January 2021

Effect of recombinant interleukin 2 on hepatitis B e antigen positive chronic hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980580-X

7 January 2021

Interleukin-2: inception, impact, and implications

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980580-X

7 January 2021

Interleukin 2 regulates expression of its receptor and synthesis of gamma interferon by human T lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980580-X

7 January 2021

Induction of circulating tumor necrosis factor (TNF alpha) as the mechanism for the febrile response to interleukin-2 (IL-2) in cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980580-X

7 January 2021

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980580-X

1 reference

7 January 2021

Antiviral effects of recombinant tumour necrosis factor in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980580-X

7 January 2021

The antiviral activity of recombinant human tumor necrosis factor-alpha

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980580-X

7 January 2021

Tumour necrosis factors alpha and beta inhibit virus replication and synergize with interferons

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980580-X

7 January 2021

Spontaneous production of tumour necrosis factor alpha and interleukin-1 beta during interferon-alpha treatment of chronic HBV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980580-X

7 January 2021

Fluctuations of plasma beta 2-microglobulin, soluble interleukin 2 receptor and interferon-gamma concentrations after adoptive immunotherapy with high-dose interleukin 2 and lymphokine-activated killer cells

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980580-X

7 January 2021

Interleukin-2 enhances biopterins and catecholamines production during adoptive immunotherapy for various cancers.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980580-X

7 January 2021

Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980580-X

7 January 2021

Quantitation of hepatitis B viral DNA by solution hybridization: comparison with DNA polymerase and hepatitis B e antigen during antiviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980580-X

7 January 2021

Demonstration of mother-to-infant transmission of hepatitis B virus by means of polymerase chain reaction

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980580-X

7 January 2021

Immune response-associated production of neopterin. Release from macrophages primarily under control of interferon-gamma

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980580-X

7 January 2021

Cytokines in the control of beta-2 microglobulin release. II. In vivo studies with recombinant interferons and antigens

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980580-X

7 January 2021

Cytokines in the control of beta-2 microglobulin release. I. In vitro studies on various haemopoietic cells

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980580-X

7 January 2021

Interleukin-2 induces profound reversible cholestasis: a detailed analysis in treated cancer patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980580-X

7 January 2021

Low-dose interleukin-2 induces systemic immune responses against HBsAg in immunodeficient non-responders to hepatitis B vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980580-X

7 January 2021

10.1016/S0168-8278(05)80580-X

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8301059%20AND%20SRC:MED&resulttype=core&format=json

29 October 2019

1 reference